# Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

> **NCT03033108** · PHASE2 · COMPLETED · sponsor: **Kubota Vision Inc.** · enrollment: 23 (actual)

## Conditions studied

- Stargardt Disease
- Macular Atrophy

## Interventions

- **DRUG:** Emixustat

## Key facts

- **NCT ID:** NCT03033108
- **Lead sponsor:** Kubota Vision Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2017-11
- **Final completion:** 2017-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03033108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03033108, "Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03033108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*